<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116152</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308A201</org_study_id>
    <nct_id>NCT03116152</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy and Safety of IBI308 and Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with
      advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment:
      a randomized, open-label, multicenter, phase 2 study
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 6 month survival rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Efficacy and Safety</condition>
  <arm_group>
    <arm_group_label>IBI308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI308 200mg Intravenous drip every three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel/irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI308</intervention_name>
    <description>IBI308 200mg Intravenous drip every three weeks；</description>
    <arm_group_label>IBI308</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>paclitaxel/ irinotecan</intervention_name>
    <description>paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks</description>
    <arm_group_label>paclitaxel/irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological confirmed, locally advanced unresectable or metastatic
             esophageal squamous cell carcinoma (not including adeno-squamous mix type or other
             pathological type)

          2. Documented disease progression (with radiographic or clinical evidence) during or
             within 16 weeks after chemotherapy containing first-line treatment; subjects must
             receive at least one dosage of first-line treatment, treatment termination, dose
             reduction of one drug or replacement among fluorouracil drugs is acceptable, treatment
             termination due to intolerable toxicity is not included; for neoadjuvant or adjuvant
             chemotherapy/chemoradiotherapy, if disease progression occurs during or within 6
             months after treatment, it should be considered as first-line therapy

          3. Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
             1.1

          4. ECOG performance status 0-1

          5. Voluntarily signed written informed consent form, willing and able to comply with
             scheduled visits and other requirements of the study

          6. Age ≥ 18 and ≤ 75

          7. Life expectancy of at least 12 weeks

          8. Subjects of reproductive potential must be willing to use adequate contraception
             during the course of the study and through 6 months after the last dose of study
             medication.

          9. Adequate organ and bone marrow function

               1. Blood routine: absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelet count
                  (PLT) ≥ 100 × 109 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.

               2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN);
                  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;
                  serum albumin ≥ 28 g / L.

               3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate
                  (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female：CrCl=
                  (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male：CrCl= (140-Age)
                  x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)

        Exclusion Criteria:

          1. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.

          2. Currently participating in a interventional clinical study, unless participating in
             observational study or during follow-up period of an interventional study.

          3. Received any investigational agent within 4 weeks of the first dose of study
             medication.

          4. Received last dose of anti-tumor therapy (chemotherapy, targeted therapy, tumor
             immunotherapy or arterial embolization) within 3 weeks of the first dose of study
             medication.

          5. Received radiotherapy with 4 weeks of the first dose of study medication.

          6. Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or
             topical steroids and adrenal replacement steroid doses are permitted in the absence of
             active autoimmune disease.

          7. Received a live vaccine within 4 weeks of the first dose of study medication or plan
             to receive live vaccine during study period.

          8. Underwent major operation (craniotomy, thoracotomy or laparotomy) within 4 weeks of
             the first dose of study medication or open wound, ulcer or fracture.

          9. Unrecovered toxicity (grade &gt;1, according to NCI CTCAE 4.03) due to prior anti-tumor
             therapy before the first dose of study medication

         10. Known symptomatic central nervous system (CNS) metastasis and/or carcinomatous
             meningitis. Subjects received prior treatment and have stable disease more than 4
             weeks from first dose of study medication, with neurological symptoms retuned to NCI
             CTCAE 4.03 grade 0 or 1, are permitted to enroll.

         11. Active, known or suspected autoimmune disease or has a history of the disease within
             the last 2 years (subjects with vitiligo, psoriasis, alopecia or Grave's disease,
             residual hypothyroidism due to autoimmune thyroiditis only requiring hormone
             replacement, or type I diabetes mellitus only requiring insulin replacement, but not
             required systemic treatment in the last 2 years, are permitted to enroll)

         12. Known primary immunodeficiency

         13. Active tuberculosis

         14. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation

         15. Known allergy or hypersensitivity to docetaxel, irinotecan or any monoclonal
             antibodies or any components used in their preparation

         16. Uncontrolled concomitant disease, including but not limited to :

               1. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)

               2. Active or poorly controlled severe infection

               3. Symptomatic congestive heart failure (New York Heart Association grade II-IV) or
                  symptomatic, poorly controlled arrhythmia

               4. Poorly controlled arterial hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg) with
                  standard treatment

               5. Prior arterial thromboembolism event, including myocardial infarction, unstable
                  angina, stroke and transient ischemic attack, within 6 months of enrollment

               6. Malnutrition requiring intravenous nutrition, subjects with malnutrition
                  correction≥4 weeks are permitted to enroll

               7. Tumor invaded to surrounding major structure (eg. aorta and bronchus)

               8. Prior esophagus or bronchus stent implantation

               9. Prior deep vein thrombosis, pulmonary embolism or any other severe
                  thromboembolism events (implanted port or catheter caused thrombosis, or
                  superficial vein thrombosis are not considered as severe thromboembolism) within
                  3 months before enrollment

              10. History of uncontrolled metabolic disorder, non-malignant organ or systemic
                  disease or secondary carcinomatous reaction, with high medical risk and/or
                  uncertainty of life expectancy evaluation

              11. With hepatic encephalopathy, hepatorenal syndrome or hepatic cirrhosis of
                  Child-Pugh grade B or higher.

              12. History of intestinal obstruction or the following diseases: inflammatory bowel
                  disease or extensive bowel resection (partial colonic resection or extensive
                  small bowel resection, concomitant with chronic diarrhea), Crohn's disease,
                  ulcerative colitis or chronic diarrhea.

              13. Other acute or chronic diseases, mental illness, or abnormal laboratory test
                  results that may lead to the following outcomes: increase the risk of
                  participating in study or study drug administration, or interfere with the
                  interpretation of the study results and considered by investigator as &quot;NOT&quot;
                  eligible to participate in this study.

         17. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or
             chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection

         18. History of gastrointestinal perforation and /or fistula within 6 months before
             enrollment

         19. Subjects with a history of interstitial lung disease

         20. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained
             or controlled

         21. Other primary malignancy, with the exception of:

               1. Curative malignancy, without active disease in the last 5 years and with very low
                  recurrence risk

               2. Non-melanoma skin cancer or malignant freckle-like nevus with adequate treatment
                  and no evidence of recurrence ;

               3. Adequately treated in-situ carcinoma

         22. Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>qi pang</last_name>
    <phone>18658868086</phone>
    <email>qi.pang@innoventbio.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

